Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Enalapril for Cardiovascular Protection after Preeclampsia

Award Number: R03HL185269
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/15/2026
PERIOD OF PERFORMANCE END DATE: 06/30/2028

Group Awards By:

View Award Description

Enalapril for Cardiovascular Protection after Preeclampsia - PROJECT SUMMARY Cardiovascular disease (CVD) is the leading cause of death in women worldwide and despite declines in all other age groups, mortality rates attributed to CVD are increasing in women of childbearing age. Preeclampsia is a well-established risk factor for CVD across all Americans, however, there are currently no evidence-based interventions targeting this at-risk patient population. While blood pressure control is the cornerstone of postpartum management, emerging evidence suggests that management of hypertension alone does not fully mitigate CVD risk after preeclampsia. The overall goal of this line of research is to begin to develop and test novel pharmacologic interventions for postpartum management following preeclampsia, representing a paradigm shift focused on cardiovascular recovery postpartum in addition to blood pressure control. Angiotensin-converting enzyme inhibitors, including enalapril, are anti-hypertensive agents that provide cardioprotection through anti-inflammatory effects and diminished fibrosis, and importantly, are recommended in non-pregnant or postpartum people with heart failure to reduce cardiovascular morbidity. In this R03 application, the objective is to conduct a single-site randomized clinical trial (RCT), which will enroll women within our institution’s remote blood pressure management program, to allow the collection of key data that will inform a future NIH-funded RCT through two specific aims: (1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum enalapril vs. standard of care, and 2) to assess the effect of postpartum enalapril on blood pressure and cardiac remodeling. Our central hypothesis is that an RCT evaluating enalapril versus standard-of-care treatments will be feasible, and that enalapril will improve blood pressure and reduce adverse cardiac remodeling at 4 months after delivery. The research proposed in this application is innovative in its novel adaptation of an evidence-based, safe strategy to improve postpartum blood pressure and cardiac remodeling in an understudied population with significant morbidity during a critical time period. This proposal is significant as it will provide an opportunity to assess the feasibility and explore the effect of enalapril on cardiac function in addition to blood pressure. Effective interventions to improve postpartum hypertension care and reduce long-term cardiovascular risk have broad implications for improving maternal morbidity and reducing disparities in care. In conjunction with my K23 award, the findings from this R03 application will provide a valuable framework to inform subsequent large-scale randomized trials of pharmacologic interventions in the postpartum period following preeclampsia. Successful completion of this line of research would represent a transformation in postpartum management of women with preeclampsia and have a direct impact to improve hypertension and cardiovascular-related maternal morbidity and mortality in the United States.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $244,569 )
2026	2026	WOMEN & INFANTS HOSPITAL OF RHODE ISLAND	101 DUDLEY ST	PROVIDENCE	RI	02905	PROVIDENCE	USA	Cardiovascular Diseases Research	000	1	7/15/2026	NEW	$244,569
														Subtotal = $244,569

Grand Total All Awards = $244,569

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Enalapril for Cardiovascular Protection after Preeclampsia

Award Number: R03HL185269

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/15/2026

PERIOD OF PERFORMANCE END DATE: 06/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer